nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

01.08.2013 | Original Paper

Magnetic resonance spectroscopy study of the glutamatergic system in adolescent males with high-functioning autistic disorder: a pilot study at 4T

verfasst von: Gagan Joshi, Joseph Biederman, Janet Wozniak, Rachel L. Goldin, Dave Crowley, Stephannie Furtak, Scott E. Lukas, Atilla Gönenç

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

The pilot study aimed at examining the neural glutamatergic activity in autism. Seven adolescent males (mean age: 14 ± 1.8; age range: 12–17 years) with intact intellectual capacity (mean IQ: 108 ± 14.26; IQ range: 85–127) suffering from autistic disorder and an equal number of age- and sex-matched healthy controls underwent a two-dimensional magnetic resonance spectroscopy scan at 4T. Results indicated significantly high glutamate (Glu) levels in the anterior cingulate cortex of autistic disorder versus control subjects (paired t test p = 0.01) and a trend for lower Glu in the right medial temporal lobe, which was not statistically different between the groups (paired t test p = 0.06). These preliminary findings support the glutamatergic dysregulation hypothesis in autism and need to be replicated in a larger sample.

Aylward EH, Minshew NJ, Goldstein G, Honeycutt NA, Augustine AM, Yates KO, Barta PE, Pearlson GD (1999) MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults. Neurology 53:2145–2150PubMedCrossRef

Bernardi S, Anagnostou E, Shen J, Kolevzon A, Buxbaum JD, Hollander E, Hof PR, Fan J (2011) In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism. Brain Res 1380:198–205PubMedCrossRef

Block W, Traber F, von Widdern O, Metten M, Schild H, Maier W, Zobel A, Jessen F (2009) Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int J Neuropsychopharmacol 12:415–422PubMedCrossRef

Boddaert N, Chabane N, Gervais H, Good CD, Bourgeois M, Plumet MH, Barthelemy C, Mouren MC, Artiges E, Samson Y, Brunelle F, Frackowiak RS, Zilbovicius M (2004) Superior temporal sulcus anatomical abnormalities in childhood autism: a voxel-based morphometry MRI study. Neuroimage 23:364–369PubMedCrossRef

Constantino JN (2002) The social responsiveness scale. Western Psychological Services, Los Angeles

DeVito TJ, Drost DJ, Neufeld RW, Rajakumar N, Pavlosky W, Williamson P, Nicolson R (2007) Evidence for cortical dysfunction in autism: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 61:465–473PubMedCrossRef

Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR (2002) Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 52:805–810PubMedCrossRef

Friedman SD, Shaw DW, Artru AA, Dawson G, Petropoulos H, Dager SR (2006) Gray and white matter brain chemistry in young children with autism. Arch Gen Psychiatry 63:786–794PubMedCrossRef

Friedman SD, Shaw DW, Artru AA, Richards TL, Gardner J, Dawson G, Posse S, Dager SR (2003) Regional brain chemical alterations in young children with autism spectrum disorder. Neurology 60:100–107PubMedCrossRef

10.

Golembiowska K, Zylewska A (1999) Effect of antidepressant drugs on veratridine-evoked glutamate and aspartate release in rat prefrontal cortex. Pol J Pharmacol 51:63–70PubMed

11.

Golembiowska K, Dziubina A (2000) Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Pol J Pharmacol 52:441–448PubMedCrossRef

12.

Gonenc A, Govind V, Sheriff S, Maudsley AA (2010) Comparison of spectral fitting methods for overlapping J-coupled metabolite resonances. Magn Reson Med 64:623–628PubMedCrossRef

13.

Goto N, Yoshimura R, Kakeda S, Nishimura J, Moriya J, Hayashi K, Katsuki A, Hori H, Umene-Nakano W, Ikenouchi-Sugita A, Korgoi Y, Nakamura J (2012) Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatr Dis Treat 8:119–122PubMed

14.

Govindaraju V, Young K, Maudsley AA (2000) Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 13:129–153PubMedCrossRef

15.

Gruber O, Hasan A, Scherk H, Wobrock T, Schneider-Axmann T, Ekawardhani S et al (2012) Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. Eur Arch Psychiatry Clin Neurosci 262:23–31PubMedCrossRef

16.

Harada M, Taki MM, Nose A, Kubo H, Mori K, Nishitani H, Matsuda T (2011) Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument. J Autism Dev Disord 41:447–454PubMedCrossRef

17.

Haznedar MM, Buchsbaum MS, Metyger M, Solimando A, Spiegel-Cohen J, Hollander E (1997) Anterior cingulate gyrus volume and glucose metabolism in autistic disorder. Am J Psychiatry 154:158

18.

Henry ME, Lauriat TL, Shanahan M, Renshaw PF, Jensen JE (2010) Accuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: a phantom study at 4Tesla. J Magn Reson 208:210–218

19.

Jamain S, Betancur C, Quach H, Philippe A, Fellous M, Giros B, Gillberg C, Leboyer M, Bourgeron T (2002) Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry 7:302–310PubMedCrossRef

20.

Jensen JE, Licata SC, Ongur D, Friedman SD, Prescot AP, Henry ME, Renshaw PF (2009) Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. NMR Biomed 22:762–769PubMedCrossRef

21.

Kemper TL, Bauman M (1998) Neuropathology of infantile autism. J Neuropathol Exp Neurol 57:645–652PubMedCrossRef

22.

Lappalainen R, Riikonen RS (1996) High levels of cerebrospinal fluid glutamate in Rett syndrome. Pediatr Neurol 15:213–216PubMedCrossRef

23.

McDougle CJ (2002) Current and emerging therapeutics of autistic disorder and related pervasive developmental disorders. In: Davis KL, Charney D, Coyle JT et al (eds) Psychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins, Philadelphia

24.

Moore CM, Frazier JA, Glod CA, Breeze JL, Dieterich M, Finn CT, Frederick B, Renshaw PF (2007) Glutamine and glutamate levels in children and adolescents with bipolar disorder: a 4.0-T proton magnetic resonance spectroscopy study of the anterior cingulate cortex. J Am Acad Child Adolesc Psychiatry 46:524–534PubMedCrossRef

25.

Musazzi L, Milanese M, Farisello P, Zappettini S, Tardito D, Barbiero VS, Bonifacino T, Mallei A, Baldelli P, Racagni G, Raiteri M, Benfenati F, Bonanno G, Popoli M (2010) Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS ONE 5:e8566PubMedCrossRef

26.

Ohnishi T, Matsuda H, Hashimoto T, Kunihiro T, Nishikawa M, Uema T, Sasaki M (2000) Abnormal regional cerebral blood flow in childhood autism. Brain 123(Pt 9):1838–1844PubMedCrossRef

27.

Page LA, Daly E, Schmitz N, Simmons A, Toal F, Deeley Q, Ambery F, McAlonan GM, Murphy KC, Murphy DG (2006) In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. Am J Psychiatry 163:2189–2192PubMedCrossRef

28.

Purcell S, Sham P (2002) Variance components models for gene-environment interaction in quantitative trait locus linkage analysis. Twin Res 5:572–576PubMed

29.

Schultz RT, Gauthier I, Klin A, Fulbright RK, Anderson AW, Volkmar F, Skudlarski P, Lacadie C, Cohen DJ, Gore JC (2000) Abnormal ventral temporal cortical activity during face discrimination among individuals with autism and Asperger syndrome. Arch Gen Psychiatry 57:331–340PubMedCrossRef

30.

Serajee FJ, Zhong H, Nabi R, Huq AH (2003) The metabotropic glutamate receptor 8 gene at 7q31: partial duplication and possible association with autism. J Med Genet 40:e42PubMedCrossRef

31.

Silk TJ, Rinehart N, Bradshaw JL, Tonge B, Egan G, O’Boyle MW, Cunnington R (2006) Visuospatial processing and the function of prefrontal-parietal networks in autism spectrum disorders: a functional MRI study. Am J Psychiatry 163:1440–1443PubMedCrossRef

32.

Smith SA, Levante TO, Meier BH, Ernst RR (1994) Computer simulations in magnetic resonance. An object-oriented programming approach. J Magn Reson A 106:75–105CrossRef

33.

Sweeten TL, Posey DJ, Shekhar A, McDougle CJ (2002) The amygdala and related structures in the pathophysiology of autism. Pharmacol Biochem Behav 71:449–455PubMedCrossRef

34.

Tarazi FI, Baldessarini RJ, Kula NS, Zhang K (2003) Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 306:1145–1151PubMedCrossRef

35.

Wechsler D (1999) Wechsler abbreviated scale of intelligence (WASI). The Psychological Corporation, San Antonio

Titel: Magnetic resonance spectroscopy study of the glutamatergic system in adolescent males with high-functioning autistic disorder: a pilot study at 4T
verfasst von: Gagan Joshi
Joseph Biederman
Janet Wozniak
Rachel L. Goldin
Dave Crowley
Stephannie Furtak
Scott E. Lukas
Atilla Gönenç
Publikationsdatum: 01.08.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 5/2013
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-012-0369-9

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder

Factors predicting the long-term illness course in a cohort of depressed inpatients

Twin-based study of the complex interplay between childhood maltreatment, socioeconomic status and adult memory

The glutamate system as a therapeutic target and impact of genes on suicidality